Abeona Therapeutics Inc. (ABEO) Stock

Abeona Therapeutics Inc. (ABEO) is a Healthcare stock trading at $5.76 (as of 2026-06-18), with a market capitalization of $323.16M and a trailing P/E of 5.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for rare genetic diseases. Its programs include EB-101 (autologous, gene-corrected cell therapy) and multiple AAV-based therapies (ABO-102, ABO-201, ABO-401, and ABO-50X) in areas such as recessive dystrophic epidermolysis bullosa, Sanfilippo syndrome type A, CLN3 disease, cystic fibrosis, and genetic eye disorders.

Valuation — source: SEC EDGAR (first-party)
Price	$5.76
Market Cap	$323.16M
P/E Ratio	5.8
EV / EBITDA	-3.0
Price / Book	2.17
Price / Sales	23.82
DCF Value (model)	$-24.13
DCF Upside vs Price	-518.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$5.82M
Net Margin	1223.1%
Return on Equity	45.6%
Debt / Equity	0.12
Current Ratio	5.89
Revenue Growth (YoY)	565.6%
EPS Growth (YoY)	25.0%
FCF Growth (YoY)	4.7%

Financial Health — source: SEC EDGAR
Altman Z-Score	-1.82 (distress)

Valuation vs Sector & Industry
Stock P/E	5.8
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-72.1%
vs Industry	-65.8%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Nantahala Capital Management, LLC ($22.46M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Vishwas Seshadri
Employees	136
Country	US
IPO Date	1996-04-01

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.